Whittam, Daniel H, Tallantyre, Emma C ![]() ![]() ![]() |
Preview |
PDF
- Accepted Post-Print Version
Download (1MB) | Preview |
Abstract
Rituximab is a widely used B-cell-depleting monoclonal antibody. It is unlicensed for use in neurological disorders and there are no treatment guidelines. However, as a rapidly acting, targeted therapy with growing evidence of efficacy and tolerability in several neuroinflammatory disorders, it is an attractive alternative to conventional immunomodulatory medications. This practical review aims to explain the basic principles of B-cell depletion with therapeutic monoclonal antibodies. We present the evidence for using rituximab in neurological diseases, and describe the practical aspects of prescribing, including dosing, monitoring, safety, treatment failure and its use in special circumstances such as coexisting viral hepatitis, pregnancy and lactation. We provide an administration guide, checklist and patient information leaflet, which can be adapted for local use. Finally, we review the safety data of rituximab and ocrelizumab (a newer and recently licensed B-cell-depleting therapy for multiple sclerosis) and suggest monitoring and risk reduction strategies.
Item Type: | Article |
---|---|
Date Type: | Publication |
Status: | Published |
Schools: | Medicine |
Publisher: | BMJ Publishing Group / Blackwell Publishing |
ISSN: | 1474-7758 |
Date of First Compliant Deposit: | 4 February 2019 |
Date of Acceptance: | 20 August 2018 |
Last Modified: | 07 Nov 2023 13:48 |
URI: | https://orca.cardiff.ac.uk/id/eprint/117275 |
Citation Data
Cited 40 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
![]() |
Edit Item |